Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 Antibody plus mFOLFIRINOX in Metastatic Pancreatic Cancer
NCT03977272Phase 2Completed
- Sponsor
- Zhejiang University
- Start
- Mar 2019
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang University. Started Mar 2019; status: completed.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03977272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977272.